Tag: nasdaq:cnce

January 28, 2020

Concert Pharmaceuticals Announces Pricing of Public Offering

Concert announced the pricing of a public offering of 4,752,420 shares of its common stock at an offering price of...
September 3, 2019

Concert Pharmaceuticals Reports Positive CTP-543 Results

Concert Pharmaceuticals (NASDAQ:CNCE) has announced topline results from its Phase 2 trial evaluating CTP-543 in patients with moderate-to-severe alopecia areata....
April 10, 2019

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692

Concert Pharmaceuticals (NASDAQ:CNCE) has started an additional trial in the Phase 1 program evaluating CTP-692, a deuterium-modified form of D-serine...
January 22, 2019

Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial

Concert Pharmaceuticals (NASDAQ:CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of...